Kadimastem Ltd (KDST) - Total Liabilities
Based on the latest financial reports, Kadimastem Ltd (KDST) has total liabilities worth ILA52.41 Million ILA as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Kadimastem Ltd - Total Liabilities Trend (2010–2024)
This chart illustrates how Kadimastem Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Kadimastem Ltd Competitors by Total Liabilities
The table below lists competitors of Kadimastem Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Wing Yip Food (China) Holdings Group Limited
KQ:900340
|
Korea | ₩42.79 Million |
|
Hammerson PLC
LSE:HMSO
|
UK | GBX1.73 Billion |
|
Starr Peak Exploration Ltd
V:STE
|
Canada | CA$2.88 Million |
|
exax Inc
KQ:060230
|
Korea | ₩88.82 Billion |
|
Secuve Co. Ltd
KQ:131090
|
Korea | ₩2.88 Billion |
|
Eden Innovations Ltd
AU:EDE
|
Australia | AU$19.59 Million |
Liability Composition Analysis (2010–2024)
This chart breaks down Kadimastem Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 33.72 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kadimastem Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kadimastem Ltd (2010–2024)
The table below shows the annual total liabilities of Kadimastem Ltd from 2010 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ILA32.44 Million | +154.93% |
| 2023-12-31 | ILA12.73 Million | +4.63% |
| 2022-12-31 | ILA12.16 Million | +1.70% |
| 2021-12-31 | ILA11.96 Million | -36.56% |
| 2020-12-31 | ILA18.85 Million | -2.40% |
| 2019-12-31 | ILA19.32 Million | +145.18% |
| 2018-12-31 | ILA7.88 Million | +0.33% |
| 2017-12-31 | ILA7.85 Million | -41.05% |
| 2016-12-31 | ILA13.32 Million | +48.97% |
| 2015-12-31 | ILA8.94 Million | -14.66% |
| 2014-12-31 | ILA10.48 Million | +104.07% |
| 2013-12-31 | ILA5.13 Million | -53.76% |
| 2012-12-31 | ILA11.10 Million | +39.05% |
| 2011-12-31 | ILA7.98 Million | +10.08% |
| 2010-12-31 | ILA7.25 Million | -- |
About Kadimastem Ltd
Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases. Its products in pipeline include AstroRx, a clinical grade human astrocytes that is in Phase 1/2a clinical trial for the treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; and IsletRx, a cli… Read more